NQF names Kennedy VP for health IT

Jeff Byers | | Health Exec | Economics
The National Quality Forum (NQF) has named Rosemary Kennedy, PhD, vice president for health IT. Kennedy joins NQF from Siemens Medical Solutions, where for seven years she was the chief nursing informatics officer.

According to the Washington, D.C.-based NQF, Kennedy will provide leadership and strategic direction to NQF’s health IT portfolio, including efforts to promote e-measure development and implementation, new versions of the quality data model and enhancements to the measure authoring tool, a web-based tool for building standardized e-measures.

During her time at Siemens, Kennedy shaped the organization’s vision and provided leadership to develop and implement clinical information tools. She is currently an associate professor in Thomas Jefferson University’s School of Nursing in Philadelphia.

Jeff Byers

Related Content

Merck spends up to $2B to license new weight loss drug with potential heart benefits
Insulet wins $452M in lawsuit against rivals over medical device trade secrets
Medical device company cuts 70% of staff in push to meet Medtronic obligations
Cleerly’s momentum continues as AI specialists raise $106M
Operations manager, doctors charged in $70M imaging kickback scheme
Private-equity watchdog warns against nominating Marc Rowan as Treasury Secretary

Around the web

Cardiovascular Business
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

AI in Healthcare
From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Cardiovascular Business
Merck spends up to $2B to license new weight loss drug with potential heart benefits

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.